Literature DB >> 16828674

Four different study designs to evaluate vaccine safety were equally validated with contrasting limitations.

Jason M Glanz1, David L McClure, Stanley Xu, Simon J Hambidge, Martin Lee, Margarette S Kolczak, Ken Kleinman, John P Mullooly, Eric K France.   

Abstract

OBJECTIVE: We conducted a simulation study to empirically compare four study designs [cohort, case-control, risk-interval, self-controlled case series (SCCS)] used to assess vaccine safety. STUDY DESIGN AND METHODS: Using Vaccine Safety Datalink data (a Centers for Disease Control and Prevention-funded project), we simulated 250 case sets of an acute illness within a cohort of vaccinated and unvaccinated children. We constructed the other three study designs from the cohort at three different incident rate ratios (IRRs, 2.00, 3.00, and 4.00), 15 levels of decreasing disease incidence, and two confounding levels (20%, 40%) for both fixed and seasonal confounding. Each of the design-specific study samples was analyzed with a regression model. The design-specific beta; estimates were compared.
RESULTS: The beta; estimates of the case-control, risk-interval, and SCCS designs were within 5% of the true risk parameters or cohort estimates. However, the case-control's estimates were less precise, less powerful, and biased by fixed confounding. The estimates of SCCS and risk-interval designs were biased by unadjusted seasonal confounding.
CONCLUSIONS: All the methods were valid designs, with contrasting strengths and weaknesses. In particular, the SCCS method proved to be an efficient and valid alternative to the cohort method.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16828674     DOI: 10.1016/j.jclinepi.2005.11.012

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  23 in total

1.  Risk of confirmed Guillain-Barre syndrome following receipt of monovalent inactivated influenza A (H1N1) and seasonal influenza vaccines in the Vaccine Safety Datalink Project, 2009-2010.

Authors:  Sharon K Greene; Melisa Rett; Eric S Weintraub; Lingling Li; Ruihua Yin; Anthony A Amato; Doreen T Ho; Sarah I Sheikh; Bruce H Fireman; Matthew F Daley; Edward A Belongia; Steven J Jacobsen; Roger Baxter; Tracy A Lieu; Martin Kulldorff; Claudia Vellozzi; Grace M Lee
Journal:  Am J Epidemiol       Date:  2012-05-11       Impact factor: 4.897

2.  A comparison of the empirical performance of methods for a risk identification system.

Authors:  Patrick B Ryan; Paul E Stang; J Marc Overhage; Marc A Suchard; Abraham G Hartzema; William DuMouchel; Christian G Reich; Martijn J Schuemie; David Madigan
Journal:  Drug Saf       Date:  2013-10       Impact factor: 5.606

3.  The safety of live attenuated influenza vaccine in children and adolescents 2 through 17 years of age: A Vaccine Safety Datalink study.

Authors:  Matthew F Daley; Christina L Clarke; Jason M Glanz; Stanley Xu; Simon J Hambidge; James G Donahue; James D Nordin; Nicola P Klein; Steven J Jacobsen; Allison L Naleway; Michael L Jackson; Grace Lee; Jonathan Duffy; Eric Weintraub
Journal:  Pharmacoepidemiol Drug Saf       Date:  2017-11-17       Impact factor: 2.890

4.  Use of FDA's Sentinel System to Quantify Seizure Risk Immediately Following New Ranolazine Exposure.

Authors:  Efe Eworuke; Emily C Welch; Anne Tobenkin; Judith C Maro
Journal:  Drug Saf       Date:  2019-07       Impact factor: 5.606

5.  Bias from outcome misclassification in immunization schedule safety research.

Authors:  Sophia R Newcomer; Martin Kulldorff; Stan Xu; Matthew F Daley; Bruce Fireman; Edwin Lewis; Jason M Glanz
Journal:  Pharmacoepidemiol Drug Saf       Date:  2018-01-02       Impact factor: 2.890

6.  Vaccine effectiveness of live attenuated and trivalent inactivated influenza vaccination in 2010/11 to 2015/16: the SIVE II record linkage study.

Authors:  Colin R Simpson; Nazir I Lone; Kim Kavanagh; Tanya Englishby; Chris Robertson; Jim McMenamin; Beatrix von Wissman; Eleftheria Vasileiou; Christopher C Butler; Lewis D Ritchie; Rory Gunson; Jürgen Schwarze; Aziz Sheikh
Journal:  Health Technol Assess       Date:  2020-12       Impact factor: 4.014

7.  Risk of febrile seizures after first dose of measles-mumps-rubella-varicella vaccine: a population-based cohort study.

Authors:  Shannon E MacDonald; Douglas C Dover; Kimberley A Simmonds; Lawrence W Svenson
Journal:  CMAJ       Date:  2014-06-09       Impact factor: 8.262

8.  Rates of adverse events associated with male circumcision in U.S. medical settings, 2001 to 2010.

Authors:  Charbel El Bcheraoui; Xinjian Zhang; Christopher S Cooper; Charles E Rose; Peter H Kilmarx; Robert T Chen
Journal:  JAMA Pediatr       Date:  2014-07       Impact factor: 16.193

9.  A scan statistic for identifying optimal risk windows in vaccine safety studies using self-controlled case series design.

Authors:  Stanley Xu; Simon J Hambidge; David L McClure; Matthew F Daley; Jason M Glanz
Journal:  Stat Med       Date:  2013-01-10       Impact factor: 2.373

Review 10.  Analytic and Data Sharing Options in Real-World Multidatabase Studies of Comparative Effectiveness and Safety of Medical Products.

Authors:  Sengwee Toh
Journal:  Clin Pharmacol Ther       Date:  2020-01-24       Impact factor: 6.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.